Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Truist starts ImmunoGen at Buy, sees share boost from full approval for Elahere » 07:28
11/21/22
11/21
07:28
11/21/22
07:28
IMGN

ImmunoGen

$5.23 /

+0.07 (+1.36%)

Truist analyst Asthika…

Truist analyst Asthika Goonewarden initiated coverage of ImmunoGen with a Buy rating and $10 price target. The stock has reacted negatively to its very recent maiden conditional approval, which suggests that investors are still concerned that the confirmatory trial will fail, but the company is on the home stretch and will ultimately prevail in receiving full approval for Elahere, the analyst tells investors in a research note. This should unshackle ImmunoGen shares, Goonewarden adds, also stating that circumstances have left a second ADC "overlooked".

ShowHide Related Items >><<
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

11/21/22 Truist
ImmunoGen initiated with a Buy at Truist
11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

  • 02
    Dec
Hot Stocks
ImmunoGen names Daniel Char as Senior Vice President and Chief Legal Officer » 06:34
11/21/22
11/21
06:34
11/21/22
06:34
IMGN

ImmunoGen

$5.23 /

+0.07 (+1.36%)

, EVLO

Evelo Biosciences

$2.08 /

-0.05 (-2.35%)

Char joins ImmunoGen…

Char joins ImmunoGen (IMGN) from Evelo Biosciences (EVLO) where he served as General Counsel and Secretary providing strategic counsel and operational support on a broad range of business and legal issues, including business development, commercialization, healthcare fraud, and intellectual property.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

EVLO Evelo Biosciences
$2.08 /

-0.05 (-2.35%)

IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

11/21/22 Truist
ImmunoGen initiated with a Buy at Truist
11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
EVLO Evelo Biosciences
$2.08 /

-0.05 (-2.35%)

11/16/22 Chardan
Evelo Biosciences downgraded to Neutral from Buy at Chardan
08/15/22 Chardan
Evelo Biosciences price target lowered to $5 from $12 at Chardan
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

EVLO Evelo Biosciences
$2.08 /

-0.05 (-2.35%)

  • 02
    Dec
Initiation
ImmunoGen initiated with a Buy at Truist » 06:27
11/21/22
11/21
06:27
11/21/22
06:27
IMGN

ImmunoGen

$5.23 /

+0.07 (+1.36%)

Truist analyst Asthika…

Truist analyst Asthika Goonewarden initiated coverage of ImmunoGen with a Buy rating and $10 price target.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
11/15/22 Barclays
ImmunoGen price target raised to $9 from $8 at Barclays
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

  • 02
    Dec
Hot Stocks
NeoGenomics, ImmunoGen launche new program for ovarian cancer patients » 09:24
11/18/22
11/18
09:24
11/18/22
09:24
NEO

NeoGenomics

$9.97 /

-1.17 (-10.51%)

, IMGN

ImmunoGen

$5.16 /

-0.02 (-0.39%)

NeoGenomics (NEO)…

NeoGenomics (NEO) launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers. Through the FR-ASSIST program, sponsored by ImmunoGen, Inc., (IMGN), EOC patients will have access to the FOLR1 IHC CDx test performed by NeoGenomics to measure the expression of a protein called folate receptor alpha. The FR-ASSIST program was launched in conjunction with the recent U.S. Food and Drug Administration's approval of ELAHERE, ImmunoGen's antibody-drug conjugate targeting FRalpha in patients with platinum-resistant EOC. The new testing program is sponsored entirely by ImmunoGen and provides eligible EOC patients with FRalpha-expression testing through NeoGenomics at no cost, regardless of insurance coverage or test results.

ShowHide Related Items >><<
NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

IMGN ImmunoGen
$5.16 /

-0.02 (-0.39%)

NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

11/14/22 Piper Sandler
NeoGenomics price target lowered to $18 from $19 at Piper Sandler
08/26/22 Benchmark
NeoGenomics downgraded to Hold from Buy at Benchmark
08/22/22 Needham
Needham cuts NeoGenomics to Hold, sees 2023 as 'transition year'
08/22/22 Needham
NeoGenomics downgraded to Hold from Buy at Needham
IMGN ImmunoGen
$5.16 /

-0.02 (-0.39%)

11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
11/15/22 Barclays
ImmunoGen price target raised to $9 from $8 at Barclays
NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

IMGN ImmunoGen
$5.16 /

-0.02 (-0.39%)

  • 02
    Dec
NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

Recommendations
ImmunoGen price target raised to $15 from $12 at Canaccord » 07:45
11/16/22
11/16
07:45
11/16/22
07:45
IMGN

ImmunoGen

$5.01 /

-0.74 (-12.88%)

Canaccord analyst John…

Canaccord analyst John Newman raised the firm's price target on ImmunoGen to $15 from $12 and keeps a Buy rating on the shares. The analyst said the FDA granted ELAHERE (mirvetuximab soravtansine) accelerated approval two weeks ahead of the 11/28/2022 action date, a major win and milestone for the company.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.01 /

-0.74 (-12.88%)

IMGN ImmunoGen
$5.01 /

-0.74 (-12.88%)

11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
11/15/22 Barclays
ImmunoGen price target raised to $9 from $8 at Barclays
11/04/22 Piper Sandler
Piper maintains 'some skepticism' on accelerated approval of ImmunoGen's mirve
IMGN ImmunoGen
$5.01 /

-0.74 (-12.88%)

  • 02
    Dec
Recommendations
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright » 06:03
11/16/22
11/16
06:03
11/16/22
06:03
IMGN

ImmunoGen

$5.01 /

-0.74 (-12.88%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on ImmunoGen to $20 from $12 and keeps a Buy rating on the shares after the company received accelerated approval from the FDA for Elahere. The analyst believes ocular toxicities could have limited impact to Elahere's adoption.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.01 /

-0.74 (-12.88%)

IMGN ImmunoGen
$5.01 /

-0.74 (-12.88%)

11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
11/15/22 Barclays
ImmunoGen price target raised to $9 from $8 at Barclays
11/04/22 Piper Sandler
Piper maintains 'some skepticism' on accelerated approval of ImmunoGen's mirve
09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
IMGN ImmunoGen
$5.01 /

-0.74 (-12.88%)

  • 02
    Dec
Recommendations
ImmunoGen approval 'best case scenario,' says Piper Sandler » 11:02
11/15/22
11/15
11:02
11/15/22
11:02
IMGN

ImmunoGen

$5.34 /

-0.41 (-7.14%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro views last night's FDA approval of Elahere on an accelerated basis as the "best case scenario" for ImmunoGen. The company received early approval with a broad label, and the FDA reviewing the interim data from the MIRASOL trial was expected, Catanzaro tells investors in a research note. However, without full details on these interim data, it is difficult to speculate on how they ultimately translate to MIRASOL's chances of success, Catanzaro tells investors in a research note. He keeps a Neutral rating on ImmunoGen with a $6 price target.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.34 /

-0.41 (-7.14%)

IMGN ImmunoGen
$5.34 /

-0.41 (-7.14%)

11/15/22 Barclays
ImmunoGen price target raised to $9 from $8 at Barclays
11/04/22 Piper Sandler
Piper maintains 'some skepticism' on accelerated approval of ImmunoGen's mirve
09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
IMGN ImmunoGen
$5.34 /

-0.41 (-7.14%)

  • 02
    Dec
Recommendations
ImmunoGen price target raised to $9 from $8 at Barclays » 06:24
11/15/22
11/15
06:24
11/15/22
06:24
IMGN

ImmunoGen

$5.74 /

+0.375 (+6.99%)

Barclays analyst Peter…

Barclays analyst Peter Lawson raised the firm's price target on ImmunoGen to $9 from $8 and keeps an Overweight rating on the shares following the FDA approval of mirvetuximab. The drug gained a broad label which beat many investor expectations with inclusion of bevacizumab naive patients, Lawson tells investors in a research note.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.74 /

+0.375 (+6.99%)

IMGN ImmunoGen
$5.74 /

+0.375 (+6.99%)

11/04/22 Piper Sandler
Piper maintains 'some skepticism' on accelerated approval of ImmunoGen's mirve
09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
IMGN ImmunoGen
$5.74 /

+0.375 (+6.99%)

  • 02
    Dec
Hot Stocks
ImmunoGen announces FDA accelerated approval of ELAHERE » 16:34
11/14/22
11/14
16:34
11/14/22
16:34
IMGN

ImmunoGen

$5.74 /

+0.375 (+6.99%)

ImmunoGen announced that…

ImmunoGen announced that the US Food and Drug Administration has granted accelerated approval for ELAHERE for the treatment of adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ELAHERE was approved under FDA's accelerated approval program based on objective response rate and duration of response data from the pivotal SORAYA trial. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. ELAHERE is a first-in-class ADC directed against FRalpha, a cell-surface protein highly expressed in ovarian cancer, and is the first FDA approved ADC for platinum-resistant disease. "The approval of ELAHERE is significant for patients with FRalpha-positive platinum-resistant ovarian cancer, which is characterized by limited treatment options and poor outcomes," said Ursula Matulonis, MD, Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, Professor of Medicine at the Harvard Medical School, and SORAYA Co-Principal Investigator. "ELAHERE's impressive anti-tumor activity, durability of response, and overall tolerability observed in SORAYA demonstrate the benefit of this new therapeutic option, and I look forward to treating patients with ELAHERE."

ShowHide Related Items >><<
IMGN ImmunoGen
$5.74 /

+0.375 (+6.99%)

IMGN ImmunoGen
$5.74 /

+0.375 (+6.99%)

11/04/22 Piper Sandler
Piper maintains 'some skepticism' on accelerated approval of ImmunoGen's mirve
09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
IMGN ImmunoGen
$5.74 /

+0.375 (+6.99%)

  • 02
    Dec
Recommendations
Piper maintains 'some skepticism' on accelerated approval of ImmunoGen's mirve » 11:55
11/04/22
11/04
11:55
11/04/22
11:55
IMGN

ImmunoGen

$5.50 /

-0.165 (-2.91%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro noted that along with reporting Q3 earnings, ImmunoGen management reiterated confidence that mirvetuximab, or "mirve," will be approved on an accelerated basis on or before the upcoming PDUFA deadline of November 28. However, he continues to "maintain some degree of skepticism around the chances of an accelerated approval" given the close proximity of the confirmatory readout and he also sees confirmatory MIRASOL study "as a trial not without risk," Catanzaro tells investors. He keeps a Neutral rating and $6 price target on ImmunoGen shares.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.50 /

-0.165 (-2.91%)

IMGN ImmunoGen
$5.50 /

-0.165 (-2.91%)

09/09/22 Barclays
ImmunoGen initiated with an Overweight at Barclays
08/31/22 Piper Sandler
Piper pushes launch estimates for ImmunoGen's pivekimab out by year after update
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
03/21/22 RBC Capital
ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital
IMGN ImmunoGen
$5.50 /

-0.165 (-2.91%)

  • 02
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.